It is known as a GLP-1 analogue (glucagon like peptide-1)
[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Chiba H, Osanai M, Murata M, Kojima T, Sawada N
According to research, the two notable modifications include the substitution of methionine and L-phenylalanine at the fourth and seventh positions with norleucine and D-phenylalanine, respectively
Safety Considerations for MS Patients Using GLP-1 Therapy Clinical evidence does not show that GLP-1 agonists trigger MS flare-ups or accelerate disease progression, but individual responses vary significantly based on disease type and current treatment regimen
By analyzing breath samples, PNO helps our medical team understand each patients unique metabolic profile, allowing personalized treatment recommendations and adjustments